NMD Pharma begins first clinical trial
NMD Pharma is pleased to announce that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, a small molecule inhibitor of skeletal muscle specific ClC-1 ion channels, into clinical trials as a novel treatment for the symptoms of myasthenia gravis.
Read more here: